Sangamo Therapeutics, Inc.

As of March 31, 2026, Sangamo Therapeutics, Inc. carries a market capitalization of 97.44M, placing it among publicly traded companies globally. Its enterprise value stands at 89.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Sangamo Therapeutics, Inc. has 414.27M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 2.19, and the price-to-book ratio stands at -5.14.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 89.18M versus a market cap of 97.44M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Sangamo Therapeutics, Inc. maintains a current ratio of 0.70, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -168.79, reflecting losses generated across the asset base. The company generates approximately 212,658.46 in revenue per employee across its workforce of 162.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2026, Sangamo Therapeutics, Inc. recorded an income tax benefit of -687,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -124.02M and -123.33M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Sangamo Therapeutics, Inc.'s stock has declined approximately 83.97% over the past 52 weeks. The 50-day moving average sits at 0.15, while the 200-day moving average is 0.22.

Over the twelve months ended March 31, 2026, Sangamo Therapeutics, Inc. generated 34.56M in revenue and converted that into -123.33M in net income, yielding earnings per share of -0.38. EBITDA reached -117.00M, while operating income came in at -110.32M.

As of March 31, 2026, Sangamo Therapeutics, Inc. holds 27.59M in cash and equivalents against 19.33M in total debt, resulting in a net debt position of -27.59M. Total book value stands at -18.95M, with working capital of -16.02M providing operational flexibility.

Sangamo Therapeutics, Inc. produced -90.34M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -115,000.00 in capital expenditures, free cash flow totaled -90.46M - equivalent to -0.28 per share.

These figures cover the twelve months ended March 31, 2026. The operating margin of -319.25 and net profit margin of -356.89 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -119.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -91.66, meaning Sangamo Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Sangamo Therapeutics, Inc. has an Altman Z-Score of -43.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.